SHAREHOLDER ALERT: Trower Given Encourages Investors Who Have Losses in Excess of $100,000,000 From Investment in ICPT. to Contact Trower Given Before the Lead Plaintiff Deadline in Class Action Lawsuit – ICPT
Intercept Pharma Could Be Bought for $493 a Share!
The end of first-quarter 2016 may be the time frame for a potential acquisition of the biotech.
Hope you are right!
Can Woodford do the same?
"We are encouraged by the reception of our enhanced positioning that outlines medical value for managing inflammation through practical dental interventions", Mr. Carbeau continued. "Medical studies now document the role of systemic inflammation in driving serious chronic diseases such as diabetes, cardiovascular disease and periodontitis. Studies also document that preventive dental care and treatment of periodontitis lower systemic inflammatory burden, and that these dental treatments provide substantial medical cost savings for patients with certain chronic diseases. PerioPredict helps identify and engage high risk patients who will benefit from these interventions. Our demand generation efforts are being focused initially on large employers and insurance carriers; we continue to make progress on both fronts."
FDA Sends Warning To Three Companies Over Direct-To-Consumer Gene Tests
The FDA letter for Interleukin Genetics referenced a 2010 correspondence where it called out the firm for the same move. Interleukin Genetics responded that theirs had been laboratory developed tests (LDTs), which currently do not need to be FDA-cleared.
The FDA, however, asserted that the test followed the DTC model and that it will continue to monitor any tests being marketed to consumers directly. In 2014, it disclosed plans to fortify its LDT oversight through enforcing pre- and post-market review for higher-risk LDTs.